Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)

被引：106

作者：

Castagneto, B. ^{[1
]}

Botta, M. ^{[1
]}

Aitini, E. ^{[2
]}

Spigno, F. ^{[7
]}

Degiovanni, D. ^{[1
]}

Alabiso, O. ^{[4
]}

Serra, M. ^{[3
]}

Muzio, A. ^{[1
]}

Carbone, R. ^{[5
]}

Buosi, R. ^{[4
]}

Galbusera, V. ^{[3
]}

Piccolini, E. ^{[6
]}

Giaretto, L. ^{[1
]}

Rebella, L. ^{[3
]}

Mencoboni, M. ^{[3
]}

机构：

[1] Novi Ligure Hosp, Dept Oncol, Novi Ligure, AL USA

[2] Osped C Poma, Dept Oncol, Mantua, Italy

[3] Osped Villa Scassi, Dept Oncol, Genoa, Italy

[4] Osped Maggiore La Carita, Dept Oncol, Novara, Italy

[5] Osped Regionale Aosta, Dept Pneumol, Aosta, Italy

[6] Osped S Spirito, Dept Pneumol, Casale Monferrato, Italy

[7] Univ Genoa, Occupat Med Unit, Genoa, Italy

来源：

ANNALS OF ONCOLOGY | 2008年 / 19卷 / 02期

关键词：

chemotherapy; mesothelioma; pemetrexed;

D O I：

10.1093/annonc/mdm501

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The aim of this study was to evaluate the activity and toxicity of pemetrexed and carboplatin combination as first-line chemotherapy in malignant pleural mesothelioma (MPM). Patients and methods: Patients with measurable advanced MPM and a zero to two Eastern Cooperative Oncology Group (ECOG) performance status (PS) were enrolled. The schedule was pemetrexed 500 mg/m(2) in combination with carboplatin area under the curve 5, every 21 days. In all, 76 patients were treated. Median age was 65 years; median ECOG PS was zero. Results: Grade 3 hematological toxicity according to World Health Organization criteria was seen in 36 (47.3%) patients; grade 4 hematological toxicity in 5 (6.5%) patients. There were 16 (21%) partial responses and 3 (4%) complete responses, for an overall response rate of 19 (25%) [95% confidence interval (CI) 15.3-34.7]. In all, 29 (39%) (95% CI 28-48) patients reported stable disease. The median survival was estimated at 14 months. Conclusion: This combination of carboplatin and pemetrexed is moderately active and the toxicity is acceptable.

引用

页码：370 / 373

页数：4

共 19 条

[1] Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent [J].